Access the full text.
Sign up today, get DeepDyve free for 14 days.
Fraser (1989)
409Crit Rev Clin Lab Sci, 27
Tin (2019)
30J Appl Lab Med, 4
P Ganz, B Heidecker, K Hveem, C Jonasson, S Kato, MR Segal (2016)
Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart diseaseJAMA, 315
Gold (2010)
e15004PLoS One, 5
Williams (2019)
1851Nat Med, 25
Anderson (2012)
250Am J Kidney Dis, 60
EN Brody, L Gold, RM Lawn, JJ Walker, D Zichi (2010)
High-content affinity-based proteomics: unlocking protein biomarker discoveryExpert Rev Mol Diagn, 10
LR Yu, J Sun, JR Daniels, Z Cao, L Schnackenberg, D Choudhury (2018)
Aptamer-based proteomics identifies mortality-associated serum biomarkers in dialysis-dependent AKI patientsKidney Int Rep, 3
ER Smith (2014)
The use of fibroblast growth factor 23 testing in patients with kidney diseaseClin J Am Soc Nephrol, 9
Kim (2018)
8382Sci Rep, 8
(2000)
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjectsJAMA, 284
J Candia, F Cheung, Y Kotliarov, G Fantoni, B Sellers, T Griesman (2017)
Assessment of variability in the SOMAscan assaySci Rep, 7
L Gold, D Ayers, J Bertino, C Bock, A Bock, EN Brody (2010)
Aptamer-based multiplexed proteomic technology for biomarker discoveryPLoS One, 5
SA Williams, M Kivimaki, C Langenberg, AD Hingorani, JP Casas, C Bouchard (2019)
Plasma protein patterns as comprehensive indicators of healthNat Med, 25
BB Sun, JC Maranville, JE Peters, D Stacey, JR Staley, J Blackshaw (2018)
Genomic atlas of the human plasma proteomeNature, 558
Smith (2014)
1283Clin J Am Soc Nephrol, 9
Yu (2018)
1202Kidney Int Rep, 3
Lopez-Silva (2022)
350Clin J Am Soc Nephrol, 17
JC Rohloff, AD Gelinas, TC Jarvis, UA Ochsner, DJ Schneider, L Gold (2014)
Nucleic acid ligands with protein-like side chains: modified aptamers and their use as diagnostic and therapeutic agentsMol Ther Nucleic Acids, 3
Levey (1999)
461Ann Intern Med, 130
Rohloff (2014)
e201Mol Ther Nucleic Acids, 3
A Tin, B Yu, J Ma, K Masushita, N Daya, RC Hoogeveen (2019)
Reproducibility and variability of protein analytes measured using a multiplexed modified aptamer assayJ Appl Lab Med, 4
JR Daniels, JZ Ma, Z Cao, RD Beger, J Sun, L Schnackenberg (2021)
Discovery of novel proteomic biomarkers for the prediction of kidney recovery from dialysis-dependent AKI patientsKidney360, 2
Candia (2022)
17147Sci Rep, 12
AS Levey, JP Bosch, JB Lewis, T Greene, N Rogers, D Roth (1999)
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study GroupAnn Intern Med, 130
C Lopez-Silva, A Surapaneni, J Coresh, J Reiser, CR Parikh, W Obeid (2022)
Comparison of aptamer-based and antibody-based assays for protein quantification in chronic kidney diseaseClin J Am Soc Nephrol, 17
JAMA, 284
Ganz (2016)
2532JAMA, 315
AH Anderson, W Yang, CY Hsu, MM Joffe, MB Leonard, D Xie (2012)
Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) studyAm J Kidney Dis, 60
Candia (2017)
14248Sci Rep, 7
Brody (2010)
1013Expert Rev Mol Diagn, 10
J Candia, GN Daya, T Tanaka, L Ferrucci, KA Walker (2022)
Assessment of variability in the plasma 7k SomaScan proteomics assaySci Rep, 12
CG Fraser, EK Harris (1989)
Generation and application of data on biological variation in clinical chemistryCrit Rev Clin Lab Sci, 27
Daniels (2021)
1716Kidney360, 2
CH Kim, SS Tworoger, MJ Stampfer, ST Dillon, X Gu, SJ Sawyer (2018)
Stability and reproducibility of proteomic profiles measured with an aptamer-based platformSci Rep, 8
Sun (2018)
73Nature, 558
BackgroundWe carried out a study of the aptamer proteomic assay, SomaScan V4, to evaluate the analytical and biological variability of the assay in plasma samples of patients with moderate to severe chronic kidney disease (CKD).MethodsPlasma samples were selected from 2 sources: (a) 24 participants from the Chronic Renal Insufficiency Cohort (CRIC) and (b) 49 patients from the Brigham and Women’s Hospital–Kidney/Renal Clinic. We calculated intra-assay variability from both sources and examined short-term biological variability in samples from the Brigham clinic. We also measured correlations of aptamer measurements with traditional biomarker assays.ResultsA total of 4656 unique proteins (4849 total aptamer measures) were analyzed in all samples. Median (interquartile range [IQR] intra-assay CV) was 3.7% (2.8–5.3) in CRIC and 5.0% (3.8–7.0) in Brigham samples. Median (IQR) biological CV among Brigham samples drawn from one individual on 2 occasions separated by median (IQR) 7 (4–14) days was 8.7% (6.2–14). CVs were independent of CKD stage, diabetes, or albuminuria but were higher in patients with systemic lupus erythematosus. Rho correlations between aptamer and traditional assays for biomarkers of interest were cystatin C = 0.942, kidney injury model-1 = 0.905, fibroblast growth factor-23 = 0.541, tumor necrosis factor receptors 1 = 0.781 and 2 = 0.843, P < 10−100 for all.ConclusionsIntra-assay and within-subject variability for SomaScan in the CKD setting was low and similar to assay variability reported from individuals without CKD. Intra-assay precision was excellent whether samples were collected in an optimal research protocol, as were CRIC samples, or in the clinical setting, as were the Brigham samples.
The Journal of Applied Laboratory Medicine – Oxford University Press
Published: Jan 27, 2023
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.